person

Ralf R.

Country
Germany
Department
6101: George-Huntington-Institut GmbH

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
18
Sites with multiple studies

Has run more than one trial at 18 of 86 partner sites.

Specializations

Neurodegenerative Disorders

The investigator specializes in the research of Huntington's Disease, with particular emphasis on understanding both prodromal and early manifest stages of the condition. Their work encompasses the evaluation of novel therapeutic approaches for managing this progressive neurological disorder.

  • Early-stage disease interventions
  • Disease progression monitoring
  • Biomarker assessment

Their research includes evaluation of cerebrospinal fluid markers and neuroimaging techniques for disease monitoring.

Therapeutic Development

The investigator focuses on evaluating emerging therapeutic compounds targeting huntingtin protein modulation. Their research encompasses assessment of various drug candidates aimed at addressing the underlying mechanisms of Huntington's Disease.

  • Protein-targeting therapeutics
  • Long-term safety evaluation
  • Drug efficacy assessment

Their work includes monitoring pharmacodynamic responses and protein level modifications in treatment approaches.

Clinical Assessment

The investigator specializes in evaluating functional capacity and clinical outcomes in Huntington's Disease patients. Their expertise includes comprehensive assessment of treatment effects using standardized rating scales.

  • Safety monitoring protocols
  • Functional assessment methods
  • Treatment response evaluation

Their research incorporates various clinical measurement tools and safety monitoring systems.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.